— Disease indication – cancer, particularly lung, breast, colon, and prostate cancer or melanoma (cancers where chemerin is down-regulated at the tumor site)
Drug format – engineered fusion protein
Drug class – first in class
Research stage and Preliminary data
Target &ndash…
— WUSTL Technology 016481
Technology Description
Researchers at Washington University in St. Louis have developed an additional targeting strategy to provide more flexibility and improve the bioactivity of the anticancer therapeutic TR3. This strategy targets TR3 to mesothelin, a tumor biomarker fr…
— WUSTL Technology 011885
Technology Description
Researchers at Washington University in St. Louis have developed a strategy to specifically target the anticancer therapeutic TR3 to cancer cells using the mesothelin/MUC16 interaction. Mesothelin is a GPI linked cell surface protein expressed in mes…
— WUSTL Technology 007646
Technology Description
Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…
— Technology Description
A team of researchers at Washington University has created a machine learning method to quickly and reliably validate patient contours in digital medical images for radiation therapy and computer aided image analysis.
Currently, automated contouring tools for delineating tu…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
